Propanc Biopharma Requests Foreign Filing License from Spain for Methods of Treating Resistant Cancer and Fibrosis
Rhea-AI Summary
Propanc Biopharma (Nasdaq: PPCB) has requested a foreign filing license from Spain for two provisional patents covering methods to treat resistant cancer and fibrosis. The provisional patents will be filed with IP Australia under Propanc Pty Ltd and are expected to be pursued in key global jurisdictions.
The fibrosis provisional is described as a world-first expansion of PRP proenzyme therapy beyond cancer. Propanc says its planned Phase 1b First‑In‑Human study in 2026 will define PRP dosing ahead of Phase 2 proof‑of‑concept studies.
Positive
- Submitted foreign filing license request to Spain for two provisional patents
- Provisional patents to be filed with IP Australia under Propanc Pty Ltd
- Planned Phase 1b First‑In‑Human PRP study scheduled for 2026
Negative
- Provisional patents only; no patent grants reported yet
- Clinical development still pre‑Phase 2; efficacy not yet demonstrated in humans
News Market Reaction
On the day this news was published, PPCB gained 5.47%, reflecting a notable positive market reaction. Argus tracked a peak move of +33.2% during that session. Argus tracked a trough of -15.4% from its starting point during tracking. Our momentum scanner triggered 27 alerts that day, indicating elevated trading interest and price volatility. This price movement added approximately $873K to the company's valuation, bringing the market cap to $17M at that time. Trading volume was exceptionally heavy at 14.5x the daily average, suggesting very strong buying interest.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Market Reality Check
Peers on Argus
Peers in Biotechnology showed mixed moves, with names like AKTX up 4.33% and RNTX up 2.67%, while LIXT and BOLD declined. With PPCB nearly flat pre‑news, this points to stock‑specific drivers rather than a coordinated sector move.
Historical Context
| Date | Event | Sentiment | Move | Catalyst |
|---|---|---|---|---|
| Dec 04 | Research program update | Positive | -4.3% | Announced EMT-focused research and PRP fibrotic patent plus 2026 Phase 1b plan. |
| Dec 01 | IP filing update | Positive | +5.5% | Requested Spanish foreign filing license for cancer and fibrosis patents. |
| Nov 17 | Earnings & corporate update | Positive | -2.8% | Reported Q1 results, PRP trial prep, GMP progress, and recent financings. |
| Nov 10 | Private placement deal | Positive | -12.4% | Secured up to $100M Series C preferred financing and warrants with Hexstone. |
| Nov 04 | Acquisition strategy | Positive | -6.2% | Announced plan to acquire digital asset treasury companies trading below MNAV. |
Recent PPCB news has largely been positive, yet 4 of 5 events saw negative next‑day reactions, suggesting a pattern of selling into good news.
Over the past few months, Propanc Biopharma has combined oncology R&D progress with an unconventional digital asset acquisition strategy. Key milestones include a strategic DAT acquisition plan on Nov 4, 2025, a large Series C preferred private placement of up to $100M, and a Q1 2025/26 update detailing PRP manufacturing, patent drafting, and cash of $600,000. The company also pursued patents and research into EMT and fibrotic disease. Today’s foreign filing license request for resistant cancer and fibrosis fits this broader push to expand PRP’s IP footprint and therapeutic scope.
Market Pulse Summary
The stock moved +5.5% in the session following this news. A strong positive reaction aligns with the company’s effort to broaden PRP’s scope beyond oncology, as seen in the new provisional patents for resistant cancer and fibrosis. Historical data show that most prior positive updates were followed by selling, with 4 of 5 recent news events posting negative next‑day moves. Investors may weigh this pattern alongside financing-related dilution risk and the long lead time to the planned 2026 Phase 1b trial when assessing sustainability.
Key Terms
fibrosis medical
extracellular matrix (ECM) medical
myocardial infarction medical
epithelial-to-mesenchymal transition (EMT) medical
Phase 1b medical
First-In-Human medical
AI-generated analysis. Not financial advice.
MELBOURNE, Australia, Dec. 01, 2025 (GLOBE NEWSWIRE) -- Propanc Biopharma, Inc. (Nasdaq: PPCB) (“Propanc” or the “Company”), a biopharmaceutical company developing novel treatments for recurrent and metastatic cancer, today announced that it has submitted a request for a foreign filing license from Spain for two provisional patents detailing new methods to treat resistant cancer and fibrosis. The patents will be filed with IP Australia under Propanc Pty Ltd, the Company’s wholly owned operating subsidiary based in Melbourne, Australia. These discoveries stem from Propanc’s Joint Research and Drug Discovery program with the Universities of Jaén and Granada in Spain and are expected to be filed subsequently in key global jurisdictions.
The first provisional patent covers methods for treating cancers that have developed resistance to chemotherapy and/or radiotherapy. Despite advancements in cancer therapies, global mortality rates remain high, and strategies to prevent recurrence are urgently needed. Treatment failure frequently occurs due to the emergence of multiple malignancies and resistance to standard therapies, underscoring the need for novel approaches.
The second provisional patent relates to compositions, methods, uses, and kits for the treatment of fibrosis, particularly organ fibrosis. Fibrosis is characterized by the excessive accumulation of scar tissue due to over-deposition of extracellular matrix (ECM) components, leading to stiffening, loss of function, and structural disruption of affected tissues. This maladaptive response can result from chronic injury or persistent inflammation and can impact nearly any organ system, including the lungs, liver, kidneys, and heart—contributing significantly to morbidity and mortality. Causes may include chronic inflammation, autoimmune and allergic responses, chemical insults, radiation, and tissue damage. For example, life expectancy following myocardial infarction-related scarring ranges from 3 to 8 years (ages 65–74), and for lung fibrosis patients is typically 3 to 5 years.
This fibrosis-related patent represents a world-first in Propanc’s intellectual property portfolio by describing the use of the Company’s lead product candidate, PRP—its proenzyme therapy—for chronic diseases beyond cancer. The biological pathways modulated by PRP to alter cancer cell behavior may also be applicable to conditions such as fibrosis. In particular, the epithelial-to-mesenchymal transition (EMT), a biological process central to embryogenesis and wound healing, plays a critical role in both tumor progression and tissue repair, making it a promising therapeutic target.
“The submission of these two patents represents a significant turning point for Propanc and the commercial potential of PRP for treating chronic diseases such as cancer and fibrosis,” said James Nathanielsz, Propanc’s Chief Executive Officer. “Our planned Phase 1b, First-In-Human study in 2026 will define the target therapeutic dose of PRP, enabling us to explore this unique proenzyme therapy across multiple disease conditions in Phase 2 proof-of-concept studies. This work will be instrumental in establishing PRP as a novel therapeutic approach that encourages cells to differentiate toward normal behavior—without the cytotoxic effects associated with many standard treatments. We are tremendously excited by these developments.”
About Propanc Biopharma, Inc.
Propanc Biopharma, Inc. (Nasdaq: PPCB) is developing a novel approach to preventing cancer recurrence and metastasis by targeting and eradicating cancer stem cells through proenzyme activation. The Company’s lead product candidate, PRP, is designed to address the underlying drivers of cancer proliferation and spread.
More information: www.propanc.com
Forward-Looking Statements
All statements in this press release that are not historical are forward-looking statements, including, among other things, statements relating to the Company’s expectations regarding its market position and market opportunity, expectations and plans as to its product development, manufacturing and sales, and relations with its partners and investors, made in reliance upon the safe harbor provisions of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These statements are not historical facts but rather are based on the Company’s current expectations, estimates, and projections regarding its business, operations and other similar or related factors. Words such as “may,” “will,” “could,” “would,” “should,” “anticipate,” “predict,” “potential,” “continue,” “expect,” “intend,” “plan,” “project,” “believe,” “estimate,” and other similar or related expressions are used to identify these forward-looking statements, although not all forward-looking statements contain these words. You should not place undue reliance on forward-looking statements because they involve known and unknown risks, uncertainties, and assumptions that are difficult or impossible to predict and, in some cases, beyond the Company’s control. Forward-looking statements are not guarantees of future actions or performance. Actual results may differ materially from those in the forward-looking statements because of several factors, including, without limitation, risks and uncertainties related to market conditions, as well as those risks described under “Risk Factors” in the prospectus related to the proposed offering and those described in the Company’s filings with the SEC. The Company undertakes no obligation to revise or update information in this release to reflect events or circumstances in the future, even if new information becomes available.
Company:
Propanc Biopharma, Inc.
James Nathanielsz
+61-3-9882-0780
info@propanc.com
Investor Contact:
irteam@propanc.com
FAQ
What patents did Propanc (PPCB) request a Spain filing license for on Dec 1, 2025?
Where will Propanc (PPCB) file the provisional patents and under which entity?
How does the fibrosis provisional patent expand PRP therapy for Propanc (PPCB)?
When will Propanc (PPCB) begin human dosing studies for PRP?
Do the provisional patents mean immediate patent protection for Propanc (PPCB)?
Will Propanc (PPCB) seek patent protection beyond Australia for these inventions?
